Beyond anti-VEGF antibodies, several tyrosine kinase inhibitors targeting VEGF- and PDGF-receptors such as sunitinib, sorafenib, and pazopanib are currently under clinical investigation in recurrent ovarian cancer [30]. This evidence concerns the gene VEGFA and ovarian carcinoma.